Substituted oxoisoindolinyl piperidine-2,6-dione compounds and aza analogs thereof
OwnerAlexandre Belin, Frederic Cachoux +6inventors
InventorsALEXANDRE BELIN, FREDERIC CACHOUX, OLGA GHERBOVET, AURELIEN HONRAEDT, THOMAS PANCALDI, JEROME SARIE, PATRICIA WALTER, PETER KINAM PARK
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein Ring A, Ring B, Y, X, R1, R3, R5a, R5b, R5c, and R7 are defined herein. Also disclosed are methods of using such compounds to decrease the level of CDK2 protein; and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of proliferative disorders, such as cancer.
Claims16
A compound of Formula (I):
- or stereoisomers, tautomers, or salts thereof, wherein:
- (i) X is CR2 and Y is CR4;
- (ii) X is CR2 and Y is N;
- (iii) X is N and Y is N;
- R1 is hydrogen or —CH3;
- R2 is hydrogen or —CH3;
- R3 is hydrogen, F, —CH3, —CHF2, or —CH2N(CH3)2;
- R4 is hydrogen;
- wherein:
- (i) R5a, R5b, and R5c are each hydrogen;
- (ii) R5a and R5b are joined together to form-CH2CH2-or —CH2OCH2—, and R5c is hydrogen;
- or
- (iii) R5a and R5c are joined together to form-CH2—, and R5b is hydrogen;
- Ring A is:
- or
- (ii) indazolyl, indolinyl, dihydrobenzofuranyl, dihydrobenzoxazinyl, tetrahydroquinolinyl, tetrahydrobenzazepinyl, or tetrahydrobenzooxazepinyl;
- Ring B is phenyl, isothiazolyl,
- R6a is hydrogen, Cl, or Br;
- R6b is hydrogen, —OH, —OCH3, —OCD3, —OCH2CH3, —OCH(CH3)2, —OCH2CH2OH, —OCH2CH2OCH3, —OCF3, —OCH2CH2F, —OCH2CH2NH2, —OCH2CH2NH(CH3), —OCH2CH2N(CH3)2, —OCH2CH2CH2NH2, —OCH2CH2CH2N(CH3)2, —OCH2CHFCH2NH2, —OCH2CF2CH2NH2, —OCH(CH3) CH2NH2, —OCH2CH(CH(CH3)2) NH2, —OCH2CH(CH3) NH2, —OCH2CH(CH2CH3) NH2, —OCH2CH(CHF2) NH2, —OCH2CH(CF3) NH2, —OCH2CH(CH2CHF2) NH2, —OCH2CH2NHC(O)CH3, —B(OH)2, —CH2CH2N(CH3)2, —NH(CH3), —N(CH3)2, —NH(CH2CH2OH), —NH(CH2CH2NH2), —NH (aminocyclobutyl), —NHC(O)CH3, —NHC(O)CH2OH, —O(cyclopropyl), —O(cyclobutyl), —O(aminocyclopentyl), —O(methylazetidinyl), —O(methyl pyrrolidinyl), —O(fluoroethyl pyrrolidinyl), —O(trifluoroethyl pyrrolidinyl), —O(methyl azaspiro[3.3]heptanyl), —OCH2(aminocyclopropyl), —OCH2(imidazolyl), —OCH2(methyl imidazolyl), —OCH2(isoxazolyl), —OCH2(oxazolyl), —OCH2(methyl pyrrolidinyl), —OCH2CH2(pyrrolidinyl), morpholinyl, oxazolyl, aminopyrrolidinyl, hydroxypyrrolidinyl, or dihydroimidazo[1,5-a]pyrazinyl;
- R6c is hydrogen or F;
- and
- R7 is hydrogen or deuterium.
The method according to claim 26, wherein said compound decreases the level of CDK2 protein and wherein said CDK21 is the amino acid sequence encoded by SEQ ID NOs:
- 1 or 2.
Dependencies are inferred from the claim text.